Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Arch Med Sci. 2012 Jul 4;8(3):528-32. doi: 10.5114/aoms.2012.29408.
Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors' critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer.
去势抵抗性前列腺癌是一个重大的临床挑战。目前，去势抵抗性前列腺癌患者的标准治疗方法是化疗，之后仅进行对症治疗。索拉非尼治疗激素难治性前列腺癌的 II 期临床试验的现有结果表明，尽管无进展生存期相对较短，但该治疗方法可能与总生存期和维持良好生活质量相关的良好结局相关。本研究介绍了作者对索拉非尼治疗前列腺癌患者的有效性的关键意见和观察。
